Financial Performance - InnoCare Pharma achieved a revenue of HKD 537 million for the first nine months of 2023, representing a year-on-year growth of 21.7%[14] - The adjusted net loss for the first nine months of 2023 was HKD 322 million, while the total net loss was HKD 539 million, a reduction of HKD 304 million compared to the same period last year[14] - The company's operating revenue for the reporting period was RMB 159.81 million, representing a decrease of 18.32% compared to the same period last year[16] - The net profit attributable to shareholders was a loss of RMB 108.96 million, with a year-to-date loss of RMB 531.17 million[16] - The company reported a net loss of RMB 4,979,423,376.98 for the first three quarters of 2023, compared to a net loss of RMB 4,448,257,868.41 in the same period of 2022[28] - The net profit attributable to shareholders of the parent company was -531,165,508.57 CNY, compared to -834,150,562.18 CNY in the previous year, showing an improvement of approximately 36.3%[31] - The total comprehensive income for the period was -337,601,250.11 CNY, compared to -279,487,002.07 CNY in the same period last year[31] Research and Development - The company is focusing on expanding its research and development capabilities, particularly in clinical trials and internal discovery projects[5] - InnoCare aims to strengthen its capabilities in discovery, clinical development, and commercialization by hiring domestic and international talents[8] - Research and development expenses totaled RMB 188.52 million, accounting for 117.97% of operating revenue, an increase of 17.26 percentage points year-on-year[16] - Research and development expenses increased to 549,716,988.65 CNY in 2023 from 475,344,994.01 CNY in 2022, reflecting a rise of about 15.6%[30] Cash and Liquidity - As of September 30, 2023, the company held cash and cash equivalents of approximately RMB 8.58 billion, ensuring sufficient cash reserves for ongoing project advancements[15] - Cash and cash equivalents as of September 30, 2023, amounted to RMB 8,261,546,048.38, a decrease from RMB 8,742,914,140.21 at the end of 2022[27] - The cash and cash equivalents at the end of the period amounted to 5,440,243,367.28 CNY, up from 4,414,372,466.48 CNY in the previous year, indicating a growth of approximately 23.2%[33] Shareholder Information - The total number of issued shares was 1,764,321,452, with 85% listed on the Hong Kong Stock Exchange[21] - The top ten shareholders collectively held 73.00% of the company's shares, with HKSCC NOMINEES LIMITED holding 41.32%[22] Strategic Plans - The company plans to utilize the remaining funds from the fundraising activities completed in February 2021 within three years, depending on actual business needs[9] - The total net amount raised from the February 2021 fundraising was approximately HKD 3,041 million[6] - The company is also reserving funds for potential external collaborations and licensing opportunities[9] - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[30] Financial Position - Total assets decreased by 2.80% to RMB 10.04 billion compared to the previous year-end[17] - The equity attributable to shareholders decreased by 3.37% to RMB 7.34 billion compared to the previous year-end[17] - Total liabilities as of September 30, 2023, were RMB 2,659,650,754.08, compared to RMB 2,684,457,313.64 at the end of 2022, showing a slight decrease of about 0.9%[28] - The company's total equity as of September 30, 2023, was RMB 7,379,971,333.29, down from RMB 7,644,326,665.47 at the end of 2022[28] Government Support - The company recognized government subsidies amounting to RMB 4.98 million during the reporting period[18] Financial Reporting - The financial data presented in the report is unaudited and based on Chinese accounting principles[1]
诺诚健华(09969) - 2023 Q3 - 季度业绩